Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR-T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR-T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR-T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR-T failure. The median number of lines of therapy between CAR-T infusion and alloHCT was 1 (range 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by haploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range 1-72). One-year overall survival, progression-free survival, and graft-versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis.

中文翻译：

---

CAR T 细胞疗法治疗大 B 细胞淋巴瘤后进行同种异体移植。

同种异体造血细胞移植 (alloHCT) 可以挽救嵌合抗原受体 T 细胞疗法 (CAR-T) 后治疗失败的大 B 细胞淋巴瘤 (LBCL) 患者。尽管如此，关于接受 CAR-T 后 alloHCT 的疗效和毒性的数据有限。我们报告了一项多中心回顾性研究，评估 CAR-T 失败后 LBCL 患者中 alloHCT 的安全性、毒性和结果。88 名复发难治性 LBCL 患者在抗 CD19 CAR-T 失败后接受了异基因 HCT。CAR-T 输注和 alloHCT 之间的中位治疗线数为 1（范围 0-7）。77%（n=68）使用低强度调节，外周血是最常见的移植来源（86%，n=76）。最常见的供体类型是匹配的无关供体（39%），其次是半相合供体（30%）和匹配的相关供体（26%）。幸存者的中位随访时间为 15 个月（范围 1-72）。一年总生存率、无进展生存率和无移植物抗宿主病无复发生存率分别为 59%、45% 和 39%。一年非复发死亡率和进展/复发分别为 22% 和 33%。关于多变量分析。